Table 1.
description of the patient characteristics, treatments and other variables
| Characteristic | All women (N = 598) | Women who did not have recurrence (N = 477) | Women who had recurrence (N = 121) | P value |
|---|---|---|---|---|
| Age, Median (IQR), year | 40 (36–53) | 40 (36–54) | 40 (36–50) | 0.272 |
| Study follow-up, Median (IQR), year | 4 (3–5) | 4 (2–5) | 4 (3–5) | 0.091 |
| Year of Diagnosis | 0.33 | |||
| 2007–2009 | 259 (43.3) | 208 (43.6) | 51 (42.1) | |
| 2010–2012 | 192 (32.1) | 147 (30.8) | 45 (37.2) | |
| 2013–2015 | 147 (24.6) | 122 (25.6) | 25 (20.8) | |
| Stage | <.0001 | |||
| 0 | 2 (0.3) | 2 (0.4) | 0 (0) | |
| I | 93 (15.6) | 84 (17.6) | 9 (7.4) | |
| II | 311 (52.0) | 270 (56.6) | 41 (33.9) | |
| III | 192 (32.1) | 121 (25.4) | 71 (58.7) | |
| Tumor grade | 0.012 | |||
| 1 | 32 (5.3) | 32 (6.7) | 0 (0.0) | |
| 2 | 211 (35.3) | 167 (35.0) | 44 (36.4) | |
| 3 | 342 (57.2) | 270 (56.6) | 72 (59.5) | |
| Unknown | 13 (2.2) | 8 (1.7) | 5 (4.1) | |
| Histology | 0.352 | |||
| Ductal | 538 (90.0) | 432 (90.6) | 106 (87.6) | |
| Lobular | 27 (4.5) | 22 (4.6) | 5 (4.1) | |
| Ductal lobular mixed | 10 (1.7) | 6 (1.3) | 4 (3.3) | |
| Other | 23 (3.8) | 17 (3.5) | 6 (5.0) | |
| ER status | 0.266 | |||
| Positive | 439 (73.4) | 355 (74.4) | 84 (69.4) | |
| Negative | 159 (26.6) | 123 (25.6) | 37 (30.6) | |
| PR status | 0.216 | |||
| Positive | 375 (62.7) | 305 (63.9) | 70 (57.8) | |
| Negative | 223 (37.3) | 172 (36.1) | 51 (42.2) | |
| HER2 status | 0.028 | |||
| Positive | 161 (26.9) | 138 (28.9) | 23 (19.0) | |
| Negative | 437 (73.1) | 339 (71.1) | 98 (81.0) | |
| Surgery | 0.003 | |||
| No surgery | 5 (0.8) | 4 (0.8) | 1 (0.8) | |
| BCS | 159 (26.6) | 141 (29.6) | 18 (14.9) | |
| Mastectomy | 434 (72.6) | 332 (69.6) | 102 (84.3) | |
| Chemotherapy | 0.614 | |||
| Yes | 547 (91.5) | 436 (91.4) | 111 (91.8) | |
| No | 40 (6.7) | 31 (6.5) | 9 (7.4) | |
| Unknown | 11 (1.8) | 10 (2.1) | 1 (0.8) | |
| Radiation therapy | 0.587 | |||
| Yes | 194 (32.4) | 150 (31.5) | 44 (36.4) | |
| No | 209 (35.0) | 169 (35.4) | 40 (33.0) | |
| Unknown | 195 (32.6) | 158 (33.1) | 37 (30.6) | |
| Hormone therapy | 0.396 | |||
| Yes | 214 (35.8) | 177 (37.1) | 37 (30.6) | |
| No | 192 (32.1) | 149 (31.2) | 43 (35.5) | |
| Unknown | 192 (32.1) | 151 (31.7) | 41 (33.9) | |
| Death | <.0001 | |||
| Yes | 92 (15.4) | 13 (2.7) | 77 (63.6) | |
| No | 506 (84.6) | 464 (97.3) | 44 (36.4) | |
| Cause of death | <.0001 | |||
| Death due to breast cancer | 76 (12.7) | 10 (2.1) | 66 (54.5) | |
| Death due to other causes | 16 (2.7) | 3 (0.6) | 11 (9.1) | |
| Alive | 506 (84.6) | 464 (97.3) | 44 (36.4) |
IQR interquartile range, ER estrogen receptor, PR progesterone receptor, HER2 Human Epidermal growth factor Receptor 2